Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Outlook Therapeutics ( (OTLK) ) has issued an announcement.
On May 13, 2026, Outlook Therapeutics entered into a new at-the-market offering agreement with H.C. Wainwright & Co. that allows the company to issue and sell up to $100 million of its common stock from time to time, with H.C. Wainwright acting as sales agent and/or principal and earning a 3% commission on gross proceeds. The arrangement, established under an already effective shelf registration, gives Outlook Therapeutics flexibility to raise capital as needed and includes standard termination rights and indemnification provisions, potentially affecting existing shareholders through future equity issuance.
In connection with the new agreement, Outlook Therapeutics terminated, effective May 12, 2026, its prior at-the-market sales agreement with BTIG, LLC, under which it had also been able to sell up to $100 million of common stock. With the end of the prior program, the company will no longer sell shares through BTIG, consolidating its at-the-market equity financing activities under the newly executed arrangement with H.C. Wainwright.
The most recent analyst rating on (OTLK) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
The score is driven down primarily by extremely weak financial performance (losses, negative equity, and heavy cash burn) and continued reliance on dilutive/strained financing. Technicals also reflect a strong downtrend, while valuation metrics are not supportive due to negative earnings. Corporate events add further risk (Nasdaq compliance and dilution), only partly offset by constructive FDA engagement.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company whose common stock is listed on The Nasdaq Capital Market. The company accesses public equity markets for financing through shelf registrations and at-the-market offering programs to support its ongoing corporate and clinical activities.
Average Trading Volume: 3,685,933
Technical Sentiment Signal: Sell
Current Market Cap: $29.28M
See more insights into OTLK stock on TipRanks’ Stock Analysis page.